Diabetes outlook dampens Sanofi's R&D pitch
This article was originally published in Scrip
Executive Summary
Despite Sanofi trying to wow investors with the headline-grabbing estimate of 18 new product launches between 2014-2020 with the potential of €30bn in sales over the first five years, the weak outlook for its diabetes drugs overshadowed the R&D update on 20 November.